NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 216 filers reported holding NEKTAR THERAPEUTICS in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11 | -99.9% | 19,000 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $10,929 | -18.2% | 19,000 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $13,355 | -78.1% | 19,000 | -0.6% | 0.00% | -81.2% |
Q3 2022 | $61,000 | -15.3% | 19,120 | 0.0% | 0.02% | -44.8% |
Q2 2022 | $72,000 | -30.1% | 19,120 | 0.0% | 0.03% | -21.6% |
Q1 2022 | $103,000 | -60.1% | 19,120 | 0.0% | 0.04% | +236.4% |
Q4 2021 | $258,000 | -24.8% | 19,120 | 0.0% | 0.01% | -91.0% |
Q3 2021 | $343,000 | +4.6% | 19,120 | 0.0% | 0.12% | -4.7% |
Q2 2021 | $328,000 | -16.5% | 19,120 | +0.6% | 0.13% | -33.3% |
Q1 2021 | $393,000 | 0.0% | 19,000 | 0.0% | 0.19% | 0.0% |
Q4 2020 | $393,000 | +69.4% | 19,000 | +35.7% | 0.19% | +40.1% |
Q3 2020 | $232,000 | -28.4% | 14,000 | 0.0% | 0.14% | -39.9% |
Q2 2020 | $324,000 | +29.6% | 14,000 | 0.0% | 0.23% | +4.6% |
Q1 2020 | $250,000 | – | 14,000 | – | 0.22% | – |
Q4 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
Q3 2019 | $52,000 | +642.9% | 2,870 | +1402.6% | 0.05% | +716.7% |
Q2 2019 | $7,000 | – | 191 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |